TBXA2R

The prevalence of idiopathic pulmonary fibrosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of idiopathic pulmonary fibrosis and the growing research and development activities to develop novel therapies to treat idiopathic pulmonary fibrosis to drive the market. The companies developing the potential therapies in the last stage of development include FibroGen, Boehringer Ingelheim, and several others. LAS VEGAS, May 25, 2023 /PRNewswire/ -- DelveInsight's ' Idiopathic Pulmonary Fibrosis Pipeline Insight – 2023 ' report provides comprehensive global coverage of pipeline idiopathic pulmonary fibrosis therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the idiopathic pulmonary fibrosis pipeline domain. Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report DelveInsight's idiopathic pulmonary fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for idiopathic pulmonary fibrosis treatment. Key idiopathic pulmonary fibrosis companies such as FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others are evaluating new idiopathic pulmonary fibrosis drugs to improve the treatment landscape. Promising idiopathic pulmonary fibrosis pipeline therapies in various stages of development include Pamrevlumab, Treprostinil, Nitric oxide inhalation - INOpulse, MN-001 (tipelukast), VAY736, ENV-101, PLN-74809, ND-L02-s0201, KD025, GKT137831, AP 01, LYT-100, TAS-115, BMS-986278, GB0139, CSL312, CC-90001, C21, BI1015550, ZSP1603, HEC585, Jaktinib Dihydrochloride Monohydrate, Ifenprodil, HZN-825, DWN12088, MG-S-2525, Saracatinib, LTI-03, BBT-877, AZD5055, KIN001-IPF, Treprostinil palmitil inhalation powder (TPIP), Brilaroxazine, ANPA 0073, SHR 1906, AK 3280, OCF 203, and others. In May 2023, Kinarus Therapeutics announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China ("CDIM"). Further, this agreement forms the basis for discussions on the introduction, development and commercialization of KIN001 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China. Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, introduced CDIM to Kinarus. In April 2023, AGC Biologics announced it signed a service agreement with The Jikei University in Japan. Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan. In February 2023, Insilico Medicine announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation to INS018_055 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). In February 2023, Arrowhead Pharmaceuticals Inc. announced that it had dosed the first subjects in a Phase I/IIa clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF). In February 2023, South Korea's Daewoong Pharmaceutical secured an exclusive licensing agreement with CS Pharmaceuticals for a first-in-class PRS inhibitor Bersiporocin in the Greater China region, including mainland China, Hong Kong, Taiwan, and Macau. Under this agreement, CSP will in-license Bersiporocin for Idiopathic Pulmonary Fibrosis (IPF) and potentially other fibrotic indications for a total consideration of up to $336 million, including up to $76 million in upfront and development milestone payments and double-digit royalties on Net Sales. In January 2023, Insilico Medicine announced the positive topline results of safety, tolerability, and pharmacokinetics (PK) from the Phase 1 clinical trial of INS018_055, a potential first-in-class drug discovered by Insilico's end-to-end AI platform for idiopathic pulmonary fibrosis (IPF). In January 2023, Pliant Therapeutics announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF). In December 2022, Vallon Pharmaceuticals announced that they entered into a definitive agreement (the "Merger Agreement") pursuant to which GRI Bio will merge with a wholly-owned subsidiary of Vallon in an all-stock transaction (the "Merger"). The combined company will focus on advancing GRI Bio's innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases. Following the closing of the Merger, the combined company is expected to operate under the name "GRI Bio, Inc." Request a sample and discover the recent advances in idiopathic pulmonary fibrosis drug treatment @ Idiopathic Pulmonary Fibrosis Pipeline Report The idiopathic pulmonary fibrosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage idiopathic pulmonary fibrosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the idiopathic pulmonary fibrosis clinical trial landscape. Idiopathic Pulmonary Fibrosis Overview Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that primarily affects middle-aged and older adults. It affects lung tissue by thickening, stiffening, or persistent and progressive scarring that worsens irreversibly over time. Scarring affects the air sacs of IPF patients, decreasing the amount of oxygen that enters the circulation. With less oxygen in the blood, ordinary tasks such as walking can cause dyspnea. This set of lung illnesses is also known as 'Diffuse Parenchymal Lung Diseases,' and it is distinguished by a broader umbrella of 'Interstitial Lung Diseases (IDLs)'. The cause of IPF is uncertain; experts believe the condition is caused by a mix of hereditary and environmental factors. There is a significant chance that genetic variations enhance a person's risk of acquiring IPF and then being exposed to environmental variables that aggravate the condition. However, much remains unknown about this new field of study. Find out more about drugs for idiopathic pulmonary fibrosis @ New Idiopathic Pulmonary Fibrosis Drugs A snapshot of the Idiopathic Pulmonary Fibrosis Pipeline Drugs mentioned in the report: Learn more about the emerging idiopathic pulmonary fibrosis pipeline therapies @ Idiopathic Pulmonary Fibrosis Clinical Trials Idiopathic Pulmonary Fibrosis Therapeutics Assessment The idiopathic pulmonary fibrosis pipeline report proffers an integral view of idiopathic pulmonary fibrosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report Coverage: Global Idiopathic Pulmonary Fibrosis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Idiopathic Pulmonary Fibrosis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Idiopathic Pulmonary Fibrosis Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravitreal, Subretinal, Topical Idiopathic Pulmonary Fibrosis Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Idiopathic Pulmonary Fibrosis Therapeutics Assessment By Mechanism of Action: Connective tissue growth factor inhibitors, 5-lipoxygenase inhibitors, Leukotriene D4 receptor antagonists, Leukotriene receptor antagonists, Phospholipase C inhibitors, Thromboxane A2 receptor antagonists, Type 3 cyclic nucleotide phosphodiesterase inhibitors, Type 4 cyclic nucleotide phosphodiesterase inhibitors, Integrin alphavbeta1 inhibitors, Integrin alphaVbeta6 inhibitors, Antibody-dependent cell cytotoxicity, Interleukin 4 receptor antagonists, SMO protein inhibitors, Galectin 3 inhibitors Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others. Key Idiopathic Pulmonary Fibrosis Pipeline Therapies: Pamrevlumab, Treprostinil, Nitric oxide inhalation - INOpulse, MN-001 (tipelukast), VAY736, ENV-101, PLN-74809, ND-L02-s0201, KD025, GKT137831, AP 01, LYT-100, TAS-115, BMS-986278, GB0139, CSL312, CC-90001, C21, BI1015550, ZSP1603, HEC585, Jaktinib Dihydrochloride Monohydrate, Ifenprodil, HZN-825, DWN12088, MG-S-2525, Saracatinib, LTI-03, BBT-877, AZD5055, KIN001-IPF, Treprostinil palmitil inhalation powder (TPIP), Brilaroxazine, ANPA 0073, SHR 1906, AK 3280, OCF 203, and others. Dive deep into rich insights for new drugs for idiopathic pulmonary fibrosis treatment; visit @ Idiopathic Pulmonary Fibrosis Medications Table of Contents For further information on the idiopathic pulmonary fibrosis pipeline therapeutics, reach out @ Idiopathic Pulmonary Fibrosis Drug Treatment Related Reports Idiopathic Pulmonary Fibrosis Market Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key idiopathic pulmonary fibrosis companies, including FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLC, among others. Idiopathic Pulmonary Fibrosis Epidemiology Forecast Idiopathic Pulmonary Fibrosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and idiopathic pulmonary fibrosis epidemiology trends. Pulmonary Fibrosis Pipeline Pulmonary Fibrosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary fibrosis companies, including Roche, Boehringer Ingelheim, Galecto Biotech, Cipla, Gilead Sciences, Fibrogen, Bristol-Myers Squibb, among others. Pulmonary Fibrosis Market Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary fibrosis companies, including Roche, Boehringer Ingelheim, Galecto Biotech, Cipla, Gilead Sciences, Fibrogen, Bristol-Myers Squibb, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

传统的非甾体抗炎药，其如影随行的胃肠道副作用一直是药学家的梦魇，但在二十世纪九十年代末，国外科学家率先发现这类药物的靶标环氧合酶（COX）存在两种同工酶——COX-1和COX-2。科学家们欣喜若狂，因为理论上高选择性COX-2抑制剂，将打破这一魔咒。随后研究者针对COX-1和COX-2在功能上的差别，研发了塞来昔布、罗非昔布等一系列非甾体抗炎药（COX-2选择抑制剂，图1）。经过数年的临床验证，表明这些选择COX-2抑制剂在疗效及胃肠道不良反应方面优于传统的非甾体抗炎药。但药物发现之路从来不是坦途。研究者在药物上市后的数年再次受创。 二十世纪末，美国食品药品监督管理局批准MERCK公司的罗非昔布上市，但在这短短五年后，通过研究发现该药可产生心梗和卒中等心血管不良反应，于是该公司宣布在全球内撤回该药[1]。随后伐地考昔也被美国FDA勒令撤出市场，还要求修改塞来昔布的说明书，强调其心血管不良反应的风险。 “山重水复疑无路，柳暗花明又一村。”我们国家的科研人员，在自身技术稍落后但时代仍在推进的情况下，刻苦钻研，成功研发出一款高效低毒的国产新药——艾瑞昔布。 中文名：艾瑞昔布（恒扬）[2]英文名称：ImrecoxibCAS号：395683-14-4分子式：C21H23NO3S结构式：见图2。 研发公司：江苏恒瑞医药化合物专利：ZL00105899.1（2001年10月24日）上市时间：2011年6月8日适应症：有效缓解关节炎等疼痛症状比如膝骨处、脊柱处。作用机制：COX-2为主要抑制靶标，炎性前列腺素的产生从而抑制，减少炎症。同时，也会较少地抑制COX-1，因此很少影响人体生理正常保护的功能。剂型与规格：片剂，0.1g。不良反应：上腹不适、大便潜血等。少见药物不良反应有：腹痛、恶心等。 该药的发展历程[3]见图3。 1.作用机制：人体正常生理保护机制[4]如图4： 那在正常情况下，抗血栓素（PGI2）与血栓素A2（TxA2）维持着血压和正常的血凝状态。而传统NSAIDs因过度抑制了COX-1而引起消化道损伤，导致能保护胃黏膜的PGI2生成减少；高选择性COX-2抑制剂使COX-2被过分抑制易产生心血管病患，造成体内抗血栓的PGI2生成减少，从而引起抗血栓素的失衡。因此，传统的COX-1与后发展的高选择性的COX-2抑制剂都导致了PGI2与TxA2的失衡。 艾瑞昔布，则根据“适度抑制”的理念创制，是在抑制炎症和疼痛的同时，继续去维持体内PGI2与TxA2的平衡，从而降低了胃肠道刺激和心血管损伤的几率。同时，我们将该药与塞来昔布进行COX选择性的比值对比[5]，通过表1更有力说明“适度抑制”到达了适量水平，因而该药是安全有效的、理想的昔布类抗炎药。 2. 构效分析： 该药的构效分析见图5。 另外，该药中不含有羧基，达到高度选择抑制的优势，即是不会干扰COX-1和COX-2 的氢键结构。与之相反的是，传统的NSAIDs则没有选择性。 3. 代谢作用： 该药经过CYP3A酶代谢，其中的4’-甲基氧化为4’-羟甲基化合物1（见图6），其t1/2较短，快速氧化代谢为4’-羧基化合物2，并以2与其葡萄糖醛酸轭合物的形式排出。那通过化学合成得到的化合产物1和2，对COX抑制活性列于表2，我们可以直观地发现这两个代谢产物的选择性和抗炎活性与该药相近[6]。 图7则是该药的合成路线图路线，其中原料3是由苯甲硫醚经F-C反应、氧化硫醚成矾，再溴化得到的。 图8则是一条更具有生产价值的新路线，将不饱和内酯通过正丙胺胺解，其不饱和内酯直接变换为不饱和内酰胺，在不改变原料的前提下，显著提高了艾瑞昔布的收率和质量。 在国内该药研发期间，国外发生了罗非昔布撤市和伐地考昔停用的事件，从而引发了对COX是否是药物靶标的质疑。经过反复学术交流，最终虽然确定了COX酶的药物靶标地位，但对胃肠道和心血管系统的不良反应不可忽视。 艾瑞昔布以郭宗儒教授的“适度抑制”理念为设计总纲，经过多次临床试验，其安全性高，耐受性好，不良事件和不良反应发生率低且程度轻，上市后11年里，无一例负面事件，无不在验证其安全、有效。“适度抑制”这一制药理念，始终在影响我们这代制药者。 参考文献 [1]李行. 罗非昔布心血管事件始末[J]. 中国处方药, 2004(11):2.[2]https://www.hengrui.com/product/innovativeMedicine.html#pie2.艾瑞昔布片说明书[3]www.docin.com/p-738768477.html?docfrom=rrela[4]郭宗儒.抗炎药物的研制——环氧合酶的适度抑制策略[J].药学学报,2005(11):7-9.DOI:10.16438/j.0513-4870.2005.11.002.[5]郭宗儒.塞来昔布和COX-2选择性抑制剂[J].药学学报,2016,51(06):1010-1016.DOI:10.16438/j.0513-4870.2014-1060.[6]郭宗儒.国家1类新药艾瑞昔布的研制[J].中国新药杂志,2012,21(3):223-230 内容来源于网络，如有侵权，请联系删除。

Los Angeles, USA, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Hepatorenal Syndrome Clinical Trial Review: Drug Development Pipeline Analysis Report Around 3+ key companies are developing therapies for Hepatorenal Syndrome. Noorik Biopharmaceuticals has its Hepatorenal Syndrome drug candidates in the mid to advanced stage (Phase II). An increase in the understanding of diagnosis and treatment of Hepatorenal Syndrome will stimulate the research and developmental activities due to the disease’s effective treatment. DelveInsight’s “Hepatorenal Syndrome Pipeline Insight” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Hepatorenal Syndrome pipeline landscapes. It comprises Hepatorenal Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Hepatorenal Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Hepatorenal Syndrome pipeline products. Some of the key takeaways from the Hepatorenal Syndrome Pipeline Report Get an overview of pipeline landscape @ Hepatorenal Syndrome Clinical Trials Analysis Hepatorenal Syndrome is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. Hepatorenal Syndrome Emerging Drugs Ambrisentan, a small molecule, is a well-characterized endothelin receptor antagonist. Ambrisentan can block the effects of endothelin on both the ETA and ETB receptors. The drug is in phase II of clinical trials for the treatment of Hepatorenal Syndrome. Ambrisentan (N-003) proved safe and well-tolerated with all subjects completing the Phase I study. Ifetroban is a potent antagonist of the thromboxane prostanoid (TPr) receptor, with several functions comprising smooth muscle contraction, platelet aggregation, and inflammation. Preclinical work on this molecule showed that inhibiting TPr with ifetroban enhances cardiac survival while increasing cardiac output in multiple animal models. The drug is in phase II of clinical trials for the treatment of Hepatorenal Syndrome. For further information, refer to the detailed report @ Hepatorenal Syndrome Pipeline Therapeutics Scope of Hepatorenal Syndrome Pipeline Drug Insight ·       Hepatorenal Syndrome Therapies Late-stage (Phase III)  ·       Hepatorenal Syndrome Therapies Mid-stage (Phase II)·       Hepatorenal Syndrome Therapies Early-stage (Phase I) ·       Hepatorenal Syndrome Preclinical stage and Discovery candidates     ·       Discontinued and Inactive candidates ·       Thromboxane A2 receptor antagonists·       Endothelin A receptor antagonists·     Vasopressin receptor agonists ·       Natural metabolites·      Monoclonal antibodies·     Small molecule ·     Subcutaneous ·      Intravenous·      Oral·      Intramuscular ·       Monotherapy·       Combination·       Mono/Combination Key Questions regarding Current Hepatorenal Syndrome Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customized pipeline report @ Hepatorenal Syndrome Drugs Pipeline Report Other Reports Browse Blog Posts About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.